Dual Therapy for Complex Inflammatory Bowel Disease: Safety, Clinical and Steroid-Free Response. (PubMed, Clin Exp Gastroenterol) - Sep 17, 2026 - "The most common combinations were adalimumab/ustekinumab in CD (46%) and adalimumab/vedolizumab in UC (35%). This study demonstrates substantial rate of clinical response and an acceptable safety profile in complex IBD patients receiving dual therapy. Still, the risk of SAEs must be balanced against the therapeutic benefit."
Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|
|
Anne-Mette Haase; Jens Kelsen; Jørgen Agnholt; Mia Bendix
|